申请人:Apodaca Richard
公开号:US20090111778A1
公开(公告)日:2009-04-30
Certain 2-keto-oxazole compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
本文描述了某些2-酮噁唑类化合物,可用作FAAH抑制剂。这些化合物可以用于药物组合物和治疗由脂肪酸酰胺水解酶(FAAH)活性介导的疾病状态,紊乱和情况的方法。因此,这些化合物可以用于治疗焦虑、疼痛、炎症、睡眠障碍、饮食障碍或运动障碍(如多发性硬化症)。